Luxdegalutamide

Target: This ligand targets the androgen receptor (AR) ligand-binding domain in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for the androgen receptor (AR) ligand-binding domain. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings the androgen receptor (AR) ligand-binding domain into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC Ligand for Degradation: Luxdegalutamide can be used as a targeting ligand within PROTAC designs to recruit an E3 ligase and drive selective ubiquitination of the associated protein. This enables systematic evaluation of degradation potency, including dose–response behavior, time dependence, and pathway dependence via proteasome and lysosome perturbation.

• Target Engagement and Selectivity: Incorporating Luxdegalutamide into PROTAC constructs supports studies of target engagement and degradation selectivity across related family members. Researchers can compare degradation profiles versus binding-only controls to distinguish true proteolysis from occupancy effects, and map structure–activity relationships that tune ternary complex formation and cellular residence time.

• Mechanistic Studies of Ubiquitination: Luxdegalutamide-based PROTACs are suitable for dissecting ubiquitin transfer mechanisms and E3 ligase recruitment efficiency. Experiments such as ubiquitination assays, E3 dependency testing, and competition with free ligand can clarify how Luxdegalutamide contributes to productive ternary complex assembly and downstream proteasomal processing.

• Proteomics-Guided Degradation Profiling: Luxdegalutamide-containing PROTACs can be leveraged for global proteome and pathway analysis to identify on-target degradation and potential off-target events. Quantitative proteomics can quantify degradation kinetics, reveal compensatory signaling, and prioritize biomarkers that reflect functional loss rather than mere target binding.

Luxdegalutamide is a androgen receptor ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Luxdegalutamide is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; halogenated aryl/heteroaryl ring system. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.